Search Results

Kallyope, Inc. today announced the initiation of their Phase 2 trial evaluating K-757 and K-833.

Kallyope, Inc. today announced the appointment of Franz Humer, Ph.D., a distinguished global industry leader in the life sciences, finance, and investment, as the new chair of its board of directors.

Kallyope , Inc. today announced that it has received $8.2 million from the Bill & Melinda Gates Foundation.

Sosei Group Corporation announced the successful identification, validation and nomination of a first G protein-coupled receptor target to enter a therapeutic discovery program for gastrointestinal diseases.

Kallyope and Brightseed have entered a strategic research collaboration to screen plant compounds to identify and validate active agents.

Kallyope, Inc., a leading biotechnology company focused on identifying and developing therapeutics involving the gut-brain axis, today announced the formation of its inaugural Clinical Development Advisory Board.

Kallyope focuses on the gut-brain axis, a bi-directional communication between the gastrointestinal tract and the brain.

“With novel compounds in two lead programs now in clinical development, this is an inflection point for Kallyope.

Kallyope, Inc., a leading biotechnology company focused on identifying and developing therapeutics involving the gut-brain axis, today announced the promotion of Shirly Pinto , Ph.D., to Chief Scientific Officer and the appointments of Jiajun Liu, Ph.D., as Vice President and Head of Biometrics and Michael Crutchlow, M.D., as Vice President and Head of Translational Medicine.

Sosei Group Corporation, the international biopharmaceutical company, and New York City-based Kallyope, pioneers in drug discovery involving the gut-brain axis, have entered a strategic research collaboration to identify and validate novel G protein-coupled receptor targets with a goal of creating new drug discovery programs in the area of gastrointestinal diseases.